Sana Biotechnology Secures $60M Series B to Accelerate Next-Gen Cell and Gene Therapies

Sana Biotechnology is proud to announce a successful funding round, having raised $60,000,000 to accelerate the development of engineered cell therapies that could redefine modern healthcare. Focused on harnessing the power of engineered cells as medicines for patients, Sana envisions a future where gene modification and cell therapies become the cornerstone of treating previously untreatable diseases. With this infusion of capital, the company aims to advance its pioneering work in three key areas that drive its mission. First, Sana is developing innovative technologies to repair and control the genes in any cell in the body, a breakthrough that promises to enable next-generation in vivo gene therapies through novel delivery systems capable of transporting any payload to any cell predictably and repeatably. Second, the company is leveraging its expertise in differentiating pluripotent stem cells ex vivo into immune-cloaked functional cells, setting the stage for the possibility of replacing damaged or missing cells, and ultimately providing new treatment avenues for patients with limited options. Third, Sana is committed to scaling manufacturing processes and lowering production costs to ensure broad access to its advanced therapies, aligning with key stakeholders to tackle challenges related to high manufacturing demands and regulatory standards. Founded in early 2019, with over 350 experts at its Seattle, Cambridge, and South San Francisco locations, Sana Biotechnology is dedicated to uniting some of the brightest minds and leading technologies to change the outcomes of many human diseases. This significant funding milestone not only fuels the company’s ambitious innovation agenda but also reinforces its long-term vision of transforming the therapeutic landscape and improving patient outcomes worldwide.